News

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old...

Functional Brands Inc. Announces P2i(TM) by Kirkman(R) as the World’s First Prenatal Supplement to Fully Align with FIGO’s Transparency Standards – and the First to Comply with California’s New SB 646 QR-Code Disclosure Law

Tata Elxsi, University of Illinois Urbana-Champaign, and OSF HealthCare Partner to Transform Rural Healthcare Access in the United States

Collaboration Leverages Digital Kiosks and AI-Driven Platforms to Bridge Healthcare GapsBENGALURU, India and CHICAGO, Dec. 2, 2025 /PRNewswire/ -- Tata...

ZAGENO Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Life Sciences E-commerce Leadership

ZAGENO earns global recognition for driving innovation, operational efficiency, and transformative customer value across the life sciences e-commerce ecosystem.SAN ANTONIO,...

GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases

Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly...

Companion Spine LLC Completes Acquisition of the Business and Assets of Paradigm Spine GmbH, including the Coflex® and CoFix® Spine Implants and All Other Implant Systems, from Xtant™ Medical Holdings, Inc.

error: Content is protected !!